Studies have found that the combination of small molecule inhibitors of HER2: TKI (e.g., pyrotinib, tucatinib, neratinib, etc.)and CDK4/6i appears to show some unexpected findings in preclinical studies of HER2+ BC. The gene discussed is CDK4; the disease is breast cancer.